NCT00473590 · REGISTRY CONDITION SEARCH

A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2017-06-14

This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or refractory multiple myeloma.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With an Overall Response

→

outcome · POSTED

Percentage of Participants With an Overall Response

→

outcome · POSTED

Duration of Response

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Number of Participants With Selected Adverse Events (AEs)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 * Previously diagnosed with multiple myeloma * Relapsed or refractory multiple myeloma with disease progression following one to three prior treatment regimens * Measurable multiple myeloma disease Exclusion Criteria: * Grade ≥ 2 peripheral neuropathy * Use of corticosteroids within 21 days prior to Day 1 * Use of other anti-myeloma therapy within 21 days prior to Day 1 * Intolerance to bortezomib or compounds containing boron * Life expectancy of \< 12 weeks * Current, recent, or planned participation in an experimental drug study * Active malignancy other than multiple myeloma within 5 years before screening * Prior treatment with bevacizumab * Inadequately controlled hypertension * Prior history of hypertensive crisis or hypertensive encephalopathy * New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF) * Decreased left ventricular function at study entry * History of myocardial infarction or unstable angina within 6 months prior to Day 1 * History of stroke or transient ischemic attack within 6 months prior to Day 1 * Significant vascular disease or recent peripheral arterial thrombosis within 6 months prior to Day 1 * Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) * Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1, or anticipation of need for major surgical procedure during the course of the study * Core biopsy or other minor surgical procedure, including placement of a vascular access device within 7 days prior to Day 1 * History of abdominal fistula or gastrointestinal perforation within 6 months prior to Day 1 * Serious, non-healing wound, active ulcer, or untreated bone fracture (for pathologic bone fractures consistent with multiple myeloma, patients may be eligible if no treatment is planned) * Albuminuria * Known hypersensitivity to any component of bevacizumab * Pregnancy (positive pregnancy test) or lactation
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Participants received bortezomib 1.3 mg/m\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.
intervention Names
Drug: Bevacizumab
Drug: Bortezomib
label
Bortezomib + bevacizumab
type
EXPERIMENTAL
description
Participants received bortezomib 1.3 mg/m\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.
intervention Names
Drug: Bortezomib
Drug: placebo
label
Bortezomib + placebo
type
ACTIVE_COMPARATOR

interventions

arm Group Labels
Bortezomib + bevacizumab
description
15 mg/kg administered by intravenous infusion
name
Bevacizumab
type
DRUG
arm Group Labels
Bortezomib + bevacizumab
Bortezomib + placebo
description
1.3 mg/m\^2 administered by intravenous bolus injection
name
Bortezomib
type
DRUG
arm Group Labels
Bortezomib + placebo
description
Intravenous repeating dose
name
placebo
type
DRUG

Study design

allocation

RANDOMIZED

intervention Model

PARALLEL

masking Info

masking: SINGLE
who Masked: INVESTIGATOR

primary Purpose

TREATMENT

Enrollment

count: 102
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Progression-free survival (PFS) was defined as the time from randomization to disease progression or death on study from any cause within 30 days of the last response assessment. Disease progression was determined by the investigator using the International Myeloma Working Group's (IMWG) uniform response criteria. Median PFS was estimated using Kaplan-Meier methodology. For patients who were alive at the time of the analysis and whose disease had not yet progressed, PFS was censored at the time of the last response assessment.
measure
Progression-free Survival (PFS)
time Frame
From randomization to disease progression or death on study (up to 116 weeks).

secondary Outcomes

description
Overall response was defined as a stringent complete response, complete response, very good partial response, or partial response (sCR, CR, VGPR, and PR, respectively) determined on two consecutive assessments ≤ 6 weeks apart and before the initiation of any new anti-tumor therapy, as assessed by the investigator using the International Myeloma Working Group's (IMWG's) uniform response criteria. Patients without a post-baseline response assessment or who died prior to their first scheduled response assessment were considered non-responders.
measure
Number of Participants With an Overall Response
time Frame
From randomization to the end of study (clinical cut-off; up to 116 weeks).
description
Overall response was defined as a stringent complete response, complete response, very good partial response, or partial response (sCR, CR, VGPR, and PR) determined on two consecutive assessments ≤ 6 weeks apart and before the initiation of any new anti-tumor therapy, as assessed by the investigator using the IMWG's uniform response criteria. Patients without a post-baseline response assessment or who died prior to their first scheduled response assessment were considered non-responders.
measure
Percentage of Participants With an Overall Response
time Frame
From randomization to the end of study (clinical cut-off; up to 116 weeks).
description
Duration of response was defined as the time from the initial response to disease progression or death on study. Disease progression was determined by the investigator using the IMWG's uniform response criteria and defined as an increase of ≥25% from best response in: Serum M-protein and/or Urine M-protein and/or Marrow plasma cells; or new or increased plasmacytomas or bone lesions; or hypercalcemia due to myeloma. Duration of response was estimated using Kaplan-Meier. For patients who had not progressed or died, duration of response was censored at the date of the last response assessment.
measure
Duration of Response
time Frame
From randomization to the end of study (clinical cut-off; up to 116 weeks).
description
Overall survival was defined as the duration of time from randomization until death from any cause. All deaths were included, whether they occurred on study treatment or following treatment discontinuation. Overall survival was estimated using Kaplan-Meier. For patients who had not died, overall survival was censored at the date that the patient was last known to be alive.
measure
Overall Survival (OS)
time Frame
From randomization until death from any cause, up until the end of study (clinical cut-off; up to 116 weeks).
description
Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), v3.0. All serious adverse events are listed in the Adverse Event Reporting section.
measure
Number of Participants With Selected Adverse Events (AEs)
time Frame
Participants were monitored for AEs from initiation of treatment to 30 days after treatment termination (up to 122 weeks).

Full study description

brief Summary: This is a randomized, blinded, placebo-controlled, multicenter, Phase II study designed to provide a preliminary assessment of the safety and efficacy of combining bevacizumab with bortezomib in patients with relapsed or refractory multiple myeloma.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-6b14a1eb48e65200076e
requested nct id
NCT00473590
primary nct id
NCT00473590
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
3830dd84c0f3caf1a09aeb5f8f4f73409b03733c8edd8b05fce62ce3c736dafa
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-6b14a1eb48e65200076e
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00473590
occurrences
context exact
NCT00473590
end
11
exact text
NCT00473590
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/626/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
9528f27740f5fa3275707340b699d006c25d6d528a0600a1b43ee603b6821481
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice